anatumomab mafenatox

Ligand id: 9947

Name: anatumomab mafenatox

Classification
Compound class Antibody
International Nonproprietary Names
INN number INN
7655 anatumomab mafenatox
Synonyms
5T4FabV13SEAD227A | ABR 214936 | ABR-214936 | ABR214936 | pMB125 | PNU 214936 | PNU-214936 | PNU214936 | TTS-CD2
Comments
Anatumomab mafenatox (ABR-214936) is a fusion protein containing an engineered 5T4 Fab moiety fused via the C terminus of the heavy chain to a mutated form of the Staphylococcal enterotoxin A (SEA) superantigen [1]. SEA is secreted by the pathogen and it stimulates a massive MHC class II-T cell receptor-mediated polyclonal T cell activation, which results in the release of large amounts of cytotoxic and proinflammatory cytokines. Anatumomab mafenatox targets the destructive power of SEA to 5T4-expressing tumour cells. The Asp227Ala mutation is the SEA moiety is designed to reduce MHC class II binding affinity so as to reduce killing of MHC class II positive cells.
Database Links
Specialist databases
IMGT/mAb-DB 287
Other databases
ChEMBL Ligand CHEMBL2108248
GtoPdb PubChem SID 374883834
Search PubMed clinical trials anatumomab mafenatox
Search PubMed titles anatumomab mafenatox
Search PubMed titles/abstracts anatumomab mafenatox